Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Thus, Dr. Nowicky is invited as an Honorable Speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
Heart Disease Research ,Acupuncture & Electro-Therapeutics Research, Integrated Medicine .
Dimitrios H. Roukos, MD, PhD, is Professor of Surgery – Precision Cancer Medicine and Founding director of “Centre for Biosystems and Genome Network Medicine” in the Ioannina University, School of Medicine. His translational and clinical research from traditional and single gene investigation to molecular networks and clinical cancer genome Next Generation Sequencing analysis has been recognized by international scientific community. He has published more than 236 PubMed papers with recent focus on Next Generation Sequencing conventional and breakthrough genome analysis more than 80 articles and more recently in precision cancer medicine (31 articles). These publications have received more than 8420 citations with h-index: 72 (Scopus). He is reviewer in many high impact journals including some with impact factor (IF) more than 30, evaluator in innovative research projects (EU, France, Belgium, Luxembourg, Poland), and member in the editorial board of 25 international journals with IF. He has been invited speaker in many international and world congresses.
Genetics, Pathology, Biomarkers, Systems biology & and cancer networks
Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA and he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University(CSU), Irvine, California, USA. He has authored more than twenty books and book chapters in different fields of Chemistry. He has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. He has multiple editorial duties in many reputed international journals, books and publishers.He is a member of more than three hundreds reputed international academic–scientific–research institutes around the world.
Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure.
Khalid Matin is currently the Medical Director of Community Oncology and Clinical Research Affiliations at the Massey Cancer Center at VCU. He coordinates the opening and closing of clinical trials at affiliate sites, including sites in Richmond and around the state of Virginia. In his role he has initiated a monthly video conference between MCC and affiliate sites to enable the discussion of clinical studies and issues that the sites may be facing. He is the co-chair of the monthly Scientific Steering Committee and have been selected to be a member of Alliance’s Community Oncology Committee at the national level. Dr Matin is also an active member of NRG Oncology's Colorectal Committee. He supervise's MCC outreach clinics at 3 rural Virginia sites, where providers see and treat cancer patients. He is also involved in organizing CME events with the affiliate partners at different sites around the state. Before joining MCC in July 2013, he was the Director of Community Oncology at Roswell Park Cancer Institute.